The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Alendronic acid effervescent tablets (Binosto®) have been accepted for restricted use in the treatment of postmenopausal osteoporosis. The restriction limits use to patients who are unable to swallow tablets where alendronic acid is the appropriate treatment choice.
Camellia sinensis (Catephen®) has been accepted for restricted use in the cutaneous treatment of external genital and perianal warts (condylomata acuminata) in immunocompetent patients from the age of 18 years. The restriction limits use to patients not suitable for podophyllotoxin or who have not responded to treatment with podophyllotoxin.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« NICE Guidance - March 2016||Corgard discontinued »|